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AbstrAct
Introduction Skin cancer is the most common 
malignancy worldwide, often occurring on the face, where 
the cosmetic outcome of treatment is paramount. A 
number of skin cancer-specific patient-reported outcome 
measures (PROMs) exist, however none adequately 
consider the difference in type of reconstruction from 
a patient’s point of view. It is the aim of this study to 
‘anglicise’ (to UK English) a recently developed US PROM 
for facial skin cancer (the FACE-Q Skin Cancer Module) 
and to validate this UK version of the PROM. The validation 
will also involve an assessment of the items for relevance 
to facial reconstruction patients. This will either validate 
this new measure for the use in clinical care and research 
of various facial reconstructive options, or provide 
evidence that a more specific PROM is required.
Methods and analysis This is a prospective validation 
study of the FACE-Q Skin Cancer Module in a UK facial 
skin cancer population with a specific focus on the 
difference between types of reconstruction. The face and 
content validity of the FACE-Q questionnaire will initially 
be assessed by a review process involving patients, skin 
cancer specialists and methodologists. An assessment of 
whether questions are relevant and any missing questions 
will be made. Initial validation will then be carried out by 
recruiting a cohort of 100 study participants with skin 
cancer of the face pre-operatively. All eligible patients will 
be invited to complete the questionnaire preoperatively 
and postoperatively. Psychometric analysis will be 
performed to test validity, reliability and responsiveness to 
change. Subgroup analysis will be performed on patients 
undergoing different forms of reconstruction postexcision 
of their skin cancer.
Ethics and dissemination This study has been approved 
by the West Midlands, Edgbaston Research Ethics 
Committee (Ref 16/WM/0445). All personal data collected 
will be anonymised and patient-specific data will only 
be reported in terms of group demographics. Identifiable 
data collected will include the patient name and date 
of birth. Other collected personal data will include their 
diagnosis, treatment performed, method of reconstruction 
and complications. A unique identifier will be applied to 
each patient so that pretreatment and post-treatment 
questionnaire results can be compared. All data acquisition 
and storage will be in accordance with the Data Protection 
Act 1998. Following completion of the study, all records 
will be stored in the Abertawe Bro Morgannwg University 
(AMBU) Health Board archive facility. Only qualified 
personnel working on the project will have access to the 
data. The outputs from this work will be published as 
widely as possible in peer-review journals and it is our aim 
to make this open access.
IntroductIon
Skin cancer is the most common malig-
nancy worldwide,1 with one in five Americans 
developing skin cancer in their lifetime.2 
The non-melanoma skin cancers (NMSC) 
greatly outweigh the number of melanomas 
diagnosed.3 In 2013, over 72 000 new NMSC 
diagnoses were made in the UK and approx-
imately 3.3 million Americans are treated 
annually for NMSC.3 4 Of the NMSCs, around 
80% of these lesions are located on the 
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Protocol
strengths and limitations of this study
 ► This is a prospective study to anglicise and further 
validate a newly developed patient-reported 
outcome measures for facial skin cancer.
 ► A strength is that this study will follow international 
standards for psychometrically testing the new 
FACE-Q Skin Cancer Module.
 ► A limitation may be that the questions in the FACE-Q 
Skin Cancer Module are found to be not sensitive 
enough to show a difference between different 
reconstructive options for facial skin cancer.
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head and neck.5 Furthermore, it is predicted that the 
number of skin cancer diagnoses is going to continue to 
increase year-on-year, with a doubling in number in the 
next 30 years, along with a fall in the average age of first 
diagnosis.6
Treatment for skin cancer is wide ranging and while 
surgical excision with a margin of non-involved tissue is 
typically favoured in Europe and the USA,7 many other 
options such as electrodessication and curettage, topical 
or intralesional chemotherapy,8 radiotherapy9 and in some 
cases laser treatment exist.10 Five-year cure rates, especially 
for excisional treatment of NMSC, are generally good and 
therefore the challenge is often reconstructing the defect 
following surgical excision, especially on the head and 
neck where cosmesis is clearly important.11 Reconstruc-
tive options include direct closure, skin grafts, local tissue 
flaps and more rarely free flaps or allowing healing by 
secondary intention. Direct closure is commonly the most 
preferable option in terms of cosmesis and reduced post-
operative complications (from a clinicians point of view), 
but in many cases it may not be possible.
In an era where shared decision-making between clini-
cians and patients is encouraged,12 it is important that the 
patient is involved in the discussion regarding the most 
appropriate reconstructive option. It is also important 
to recognise that health should be considered as ‘a state 
of physical, mental and social well-being and not just the 
absence of disease or infirmity’ and as such, the aesthetic 
and emotional outcome of various types of reconstruc-
tion is just as important as the removal of the skin malig-
nancy. To date, very little work has focused on the patient 
perspective of the difference between these reconstruc-
tive options. While patient-reported outcome measures 
(PROMs) for skin cancer exist, these are often not specific 
to the reconstruction and do not explore patients’ views 
between the different types of reconstruction.
PROMs are questionnaires where responses are 
collected directly from patients and are used to measure 
the perception and impact of a condition and its treat-
ment on their quality of life or disease severity. They are 
considered by the UK Department of Health as currently 
the best method for quantifying a patients’ clinical expe-
rience and are critical in maximising quality of care. 
Currently, only four surgical conditions have routine 
PROM data collected at a national level in the UK, 
although both generic and disease-specific PROMs are 
often employed at a local level and in clinical trials.13
A number of different PROMs have been applied 
to or designed for patients with skin cancer. A system-
atic review in 2013 demonstrated that there were two 
generic PROMs (SF-36 and Sickness Impact Profile) and 
nine skin cancer-specific PROMs (EORTC QLQ-C30, 
EORTC QLQ-M, FACT-M, FACT-BRM, SCI, FSCI, DLQI, 
Skindex and SCQOLIT).14 One of the limitations when 
these were evaluated was that for patients with NMSC, the 
scores on these measures are often comparable to popu-
lation norms. It may be that there is no ‘true’ difference 
between those with NMSC and those without, however 
it is more likely that current PROMs are not capturing 
the important aspects of quality of life in this patient 
group. Recent work by Lee and colleagues have demon-
strated the need for an improved and specific PROM for 
patients with skin cancer of the head and neck,15 which 
they have developed in the form of the FACE-Q Skin 
Cancer Module. However, no PROM to date has been 
specifically evaluated for or designed to look at the differ-
ence between varying reconstructive options post-skin 
cancer resection. In order that we are able to appropri-
ately council our patients on the different types of recon-
struction and evaluate the differences from a patients’ 
perspective, this situation needs to be addressed.
AIMs And objEctIvEs
The aim of this study is to anglicise and validate the 
FACE-Q Skin Cancer Module for use in a UK popula-
tion of patients who are undergoing reconstruction for 
a facial skin cancer. Anglicisation is an important step in 
the adoption of this new PROM into UK practice as subtle 
differences in grammar and language style can influence 
the understanding and scoring of a PROM questionnaire. 
This is a well-documented process for using a PROM orig-
inally developed in another country or language.16 We 
will undertake preliminary psychometric analysis of the 
anglicised FACE-Q to test reliability, construct validity, 
test–retest reliability and responsiveness in three specific 
groups—those patients who have undergone reconstruc-
tion either with direct closure, skin grafting or a local skin 
flap. This is with the aim of determining if the FACE-Q 
Skin Cancer Module is able to detect a difference in 
patient outcomes between these three reconstructive 
options.
MEthods And AnAlysIs
Anglicisation of the FAcE-Q skin cancer Module
The FACE-Q Skin Cancer Module will be reviewed by 
a group of skin cancer specialists (including derma-
tologists, plastic surgeons and other members of the 
multidisciplinary team) and methodologists in order to 
determine the face and content validity of the instrument. 
Face validity refers to whether the questions appear to 
be assessing the desired qualities that is, are they on the 
surface measuring what they actually are, while content 
validity is a judgement assessment of whether the items in 
a scale encompass all relevant and important areas of the 
concept being measures in appropriate detail. To ensure 
that the questionnaire is understandable and readable 
to our population group a small cohort of patients will 
then be selected to review the questionnaire. This will 
be conducted in the form of 1-to-1 cognitive interviews, 
which will be arranged to coincide with normal clinical 
follow-up and will therefore not incur any additional 
costs to the patient. Each question will be scrutinised 
for language content appropriate to a UK-based cohort 
and if needed anglicised. Prior to this stage, a systematic 
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review of the literature pertaining to both PROMs for 
facial skin cancer and PROMs for facial reconstruction 
will be conducted in order to identify any other ques-
tions which may be important in determining the differ-
ence between different reconstructive options for facial 
skin cancer. If additional questions are identified either 
through patient and clinician interviews or from other 
PROMs identified in systematic reviews, these will be 
included in the study for initial validation in our facial 
skin cancer cohort.
recruitment
A cohort of at least 100 patients will be recruited prospec-
tively from the plastic surgery department at Morriston 
Hospital, Swansea, UK over an 18-month period begin-
ning in August 2018. Invitation to participate will be 
offered to all patients presenting with a skin cancer of 
the head and neck over the age of 18 years to the Plastic 
Surgery department. Eligibility criteria for inclusion will 
be based on:
Inclusion criteria
 ► Skin cancer (all types included) of the head and neck
 ► Over 18 years of age
 ► Active treatment with wide local excision of the lesion.
Exclusion criteria
 ► Inability to consent to participation in study
 ► Known learning difficulties or dementia
 ► English language not of a standard to understand and 
complete the questionnaire
 ► Treatment of lesion with topical chemotherapy/laser 
or other methods that are not excisional
 ► Free tissue reconstruction.
Those patients who meet the inclusion criteria will be 
given an oral and written explanation of the study. If they 
wish to be involved, they will be asked to sign a consent 
form and this will be recorded in the patient notes. All 
participants will be free to withdraw their consent from 
the study at any point.
Each study participant will be asked to complete the 
FACE-Q skin cancer questionnaire either at the time of 
their clinic appointment or later at home. They will also 
complete the Facial Skin Cancer Index (FSCI) question-
naire17 and the generic European Quality of Life Five 
Dimensions (EQ5D) questionnaire.18
sample size
There are no general criteria for the required sample 
size when validating a PROM questionnaire19 although 
some believe that the number of respondents should be 
three times the number of items in the questionnaire.20 
No matter what sample size is chosen it is however 
important that the sample is representative of the popu-
lation group on which the instrument is intended to be 
used. We aim to recruit at least 100 patients so that we 
have >30 patients in each arm (eg, direct closure/skin 
graft/local flap).
Psychometric analysis
Psychometric analysis will be performed inline with the 
gold standards for instrument assessment as defined 
by the Scientific Advisory Committee of the Medical 
Outcomes Trust21 and methods outlined by Streiner and 
Norman.19 All data will be analysed using the Statistical 
Package for Social Sciences software licensed to Swansea 
University.
underlying dimensions and internal consistency
Internal consistency is one measure of reliability. It 
measures the degree of correlation between different 
items in a scale and therefore questions that are asking 
similar things should correlate. We will assess the internal 
consistency of the anglicised FACE-Q by examining item–
total correlations and Cronbach’s α. We will consider 
questions for rejection if their item–total correlations are 
<0.2 (hardly related) or >0.8 (highly related and there-
fore providing little additional information).19 Finally, 
we will examine Cronbach’s α for the total questionnaire 
score and for any factor/sub-scale scores to ensure that 
they >0.7.19
We will then apply principal components analysis to 
the data. We will consider a factor important if its eigen-
value (the power to explain variation between patients) 
>1, and that it has face validity, meaning that it appears to 
measure a recognisable aspect of the patients’ quality of 
life. We will consider a question as contributing to a factor 
if it has a factor loading of at least 0.4 on that factor. Items 
not contributing to a factor in this way will be considered 
for rejection from the questionnaire.
validity
Construct validity is a measure of the correlation of the 
scale being tested to another instrument that is believed to 
assess the same attributes with good validity and reliability. 
It is commonly measured using the Pearson correlation 
coefficient (r), with a low correlation suggesting that the 
tests either have low validity or are measuring different 
things and a high correlation suggesting that the tests 
are very similar and a new scale is not needed.22 We will 
accept the construct validity of the FACE-Q Skin Cancer 
Module if the Pearson correlation is 0.4–0.83 when tested 
against the Facial Skin Cancer Index17 and the generic 
EQ5D.18 If the anglicised FACE-Q and its subscales are 
valid measures to assess facial reconstruction we would 
expect to see small to moderate levels of correlation with 
the general health questionnaires. In addition, if any of 
the FACE-Q subscales are valid measures of facial recon-
struction we might expect to see, for example, worse 
scores on aesthetic subscales for patients who have under-
gone a more extensive surgical operation than those who 
have had less invasive surgery.
reproducibility
Reproducibility is another measure of test reliability; in 
this case, the reliability of the test to give similar scores 
on two or more occasions in the same person assuming 
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their condition has not changed. We will assess repro-
ducibility by comparing patients’ FACE-Q Skin Cancer 
Module scores at two time points postsurgery when the 
patient has stabilised, to a subsample of around 20% of 
the study population. We will administer the question-
naire at two time points postsurgery, a period of 1–2 weeks 
apart. In addition to completing the FACE-Q Skin Cancer 
Module at the second time point, each patient will be 
asked whether they consider their quality of life to have 
improved, deteriorated or stayed the same. We would 
expect that for patients who report no change in their 
symptoms that the scores will be consistent at these two 
time points. We will assess the reproducibility of the 
scores for stable patients using intraclass correlation, with 
a value of 0.75 acceptable.19
responsiveness
Responsiveness in the instrument is its ability to detect 
change in a patient’s condition. We will assess respon-
siveness of the FACE-Q Skin Cancer Module in those 
patients’ reporting either an improvement or deteriora-
tion in their condition pre-surgery and postsurgery. We 
will use Guyatt’s responsiveness statistics to quantify the 
responsiveness of the FACE-Q Skin Cancer Module.23
In order to determine if the instrument is both valid 
and sensitive enough to compare different types of recon-
struction, we will split the recruited patients into three 
population groups (those that undergo direct closure 
of the wound, skin grafting or local flap) and compare 
FACE-Q Skin Cancer Module total and subscale scores 
to determine if the questionnaire is sensitive enough to 
detect differences in scores between these three groups. 
We will use analysis of variance or non-parametric equiva-
lent tests (depending on sample size) to determine if any 
differences exist.
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